Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit

Rhea-AI Summary

Anavex Life Sciences Corp. (AVXL) announced that CEO Christopher U. Missling will present at the Precision in Clinical Trials Virtual Summit on May 10, 2021. The company focuses on developing therapeutics for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Anavex’s lead candidate, ANAVEX®2-73, has successfully completed a Phase 2a trial for Alzheimer’s and ongoing studies for Parkinson’s and Rett syndrome. The drug shows promise in restoring cellular function by targeting specific receptors and has potential benefits for multiple CNS disorders.

Positive

• ANAVEX®2-73 successfully completed Phase 2a clinical trial for Alzheimer's disease.
• Ongoing Phase 2 studies for Parkinson's disease dementia and adult Rett syndrome.
• ANAVEX®2-73 shows potential benefits for other CNS disorders, including epilepsy.

Negative

• None.

NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, “Clinical Trials for Rare Diseases: Challenges and Opportunities”, at the Precision in Clinical Trials Virtual Summit (East Coast) on Monday, May 10^th at 9:35 a.m. EDT. The Precision in Clinical Trials Virtual Summit (East Coast) takes place May 10^th - 11^th 2021.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), completed successfully a Phase 2a clinical trial for Alzheimer’s disease and recently a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations

Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

When will Anavex present at the Precision in Clinical Trials Virtual Summit?

Anavex will present on May 10, 2021, at 9:35 a.m. EDT.

What is the status of ANAVEX®2-73 in clinical trials?

ANAVEX®2-73 has completed a Phase 2a clinical trial for Alzheimer’s and is undergoing trials for Parkinson’s disease dementia and Rett syndrome.

What diseases does Anavex Life Sciences focus on?

Anavex specializes in therapeutics for neurodegenerative disorders such as Alzheimer's, Parkinson's, and Rett syndrome.

What are the potential benefits of ANAVEX®2-73?

ANAVEX®2-73 may restore cellular homeostasis and shows promise for treating multiple CNS disorders.